Figure 3
Figure 3. Analysis of the sensitivity of RA3331/E6E7/hTERT cell lines expressing SLX4 mutants to MMC, CPT, and PARP inhibitor. (A) MMC sensitivity in RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. (B) CPT sensitivity in RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. (C) PARP inhibitor sensitivity assay of RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. RA3331/E6E7/hTERT fibroblast cell lines expressing WT SLX4, empty vector, SLX4 UBZ mut, SLX4 ΔMLR, SLX4 ΔSAP, and SLX4 ΔSBD were treated in triplicate with increasing concentrations of MMC (0-100nM), CPT (0-16nM), and PARP inhibitor (0-10μM). After 8 days in culture, the cell number was determined using a Coulter counter. The number of cells at each drug concentration was divided by the number of cells in the untreated sample to calculate the percentage of cell survival. The error bars represent SD from 3 replicates. Sensitivity assays in cells expressing the other SLX4 mutants used in this study are shown in supplemental Figure 3.

Analysis of the sensitivity of RA3331/E6E7/hTERT cell lines expressing SLX4 mutants to MMC, CPT, and PARP inhibitor. (A) MMC sensitivity in RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. (B) CPT sensitivity in RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. (C) PARP inhibitor sensitivity assay of RA3331/E6E7/hTERT cell lines expressing indicated SLX4 mutants. RA3331/E6E7/hTERT fibroblast cell lines expressing WT SLX4, empty vector, SLX4 UBZ mut, SLX4 ΔMLR, SLX4 ΔSAP, and SLX4 ΔSBD were treated in triplicate with increasing concentrations of MMC (0-100nM), CPT (0-16nM), and PARP inhibitor (0-10μM). After 8 days in culture, the cell number was determined using a Coulter counter. The number of cells at each drug concentration was divided by the number of cells in the untreated sample to calculate the percentage of cell survival. The error bars represent SD from 3 replicates. Sensitivity assays in cells expressing the other SLX4 mutants used in this study are shown in supplemental Figure 3.

Close Modal

or Create an Account

Close Modal
Close Modal